Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.

Reference strains of HIV-1 from the NIH AIDS Research and Reference Reagent Program, including wild-type IIIB, G762-3, and AZT resistant with RT 215T-->Y (G910-11/AZT); 67D-->N, 70K-->R, 215T-->F, 219K-->Q (G691-2/AZT); as well as nevirapine (NEV) resistant with 181Y-->C (N119/NEV); and 103K-->N, 181Y-->C (A17/NEV), were subjected to quantitative parametric efficacy analysis using AZT, stavudine (D4T), and nevirapine (NEV) singly or in combinations in MT4 or MT2 cells. The median-effect principle and combination index (CI) method of Chou-Talalay (see Ref. 26) have been used, which take into account both the potency (Dm value or EC50) and the shape of the dose-effect curve (m value). Under standardized assay conditions, G910-11 and G691-2 strains showed 600- and 7800-fold resistance to AZT, and N119 and A17 strains showed 3600- and 1000-fold resistance to NEV at the EC50 level, respectively. AZT-resistant strains exhibited slight cross-resistance to D4T. Computerized analysis indicates that IIIB gave sigmoidal dose-effect curves (m = 2.8, 3.4, and 3.1 for AZT, D4T, and NEV, respectively) whereas drug-resistant strains showed negative sigmoidicity toward the corresponding AZT or NEV, with m = 0.27-0.73. Therefore, the degrees of drug resistance are drastically different at classic EC50 and at therapeutically more relevant EC95 levels (ranging from severalfold to several log orders). Combinations of AZT+NEV and AZT+NEV+D4T showed synergism against IIIB, G762-3 (wild type) and A17/NEV, G910-11/AZT strains. D4T+NEV and AZT+D4T showed nearly additive or moderate antagonism. Synergism or additive effect leads to a favorable dose-reduction index (DRI). The present study on RT inhibitors provides quantitative assessment of the combinations of AZT, NEV, and D4T against HIV infections involving drug-sensitive and drug-resistant HIVs.

[1]  L. Vrang,et al.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet , 1989, Antimicrobial Agents and Chemotherapy.

[2]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[3]  Mark L. Pearson,et al.  Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.

[4]  P. Gøtzsche,et al.  Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. , 1992, Antiviral research.

[5]  J. Oxford,et al.  Sequence analysis of an HIV‐1 isolate which displays unusually high‐level AZT resistance in vitro , 1992, Journal of medical virology.

[6]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[7]  J. Hansen,et al.  Evaluation of the combination effect of different antiviral compounds against HIV in vitro. , 1993, Scandinavian journal of infectious diseases.

[8]  T. Chou,et al.  Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. , 1976, Journal of theoretical biology.

[9]  E. Clercq.  HIV resistance to reverse transcriptase inhibitors , 1994 .

[10]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[11]  J. Craig,et al.  In vitro anti-HIV and Cytotoxicological Evaluation of the Triple Combination: AZT and ddC with HIV Proteinase Inhibitor Saquinavir (Ro 31-8959) , 1994 .

[12]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[14]  Broder,et al.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Ho,et al.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.

[16]  D. McPhee,et al.  Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. , 1990, The Journal of infectious diseases.

[17]  D. Richman.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.

[18]  J. Proudfoot,et al.  A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. , 1991, Biochemistry.

[19]  S D Kemp,et al.  Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture , 1991, Journal of virology.

[20]  D. Katzenstein,et al.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.

[21]  D. Richman,et al.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S D Kemp,et al.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.

[23]  D. Richman,et al.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[24]  S D Kemp,et al.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.

[25]  M. Hirsch,et al.  Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro , 1994, Antimicrobial Agents and Chemotherapy.

[26]  T. Chou,et al.  In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors , 1990, Antimicrobial Agents and Chemotherapy.

[27]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[28]  B. Jacobsson,et al.  Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. , 1991, AIDS research and human retroviruses.

[29]  R. Schinazi,et al.  Insights into HIV chemotherapy. , 1992, AIDS research and human retroviruses.

[30]  M. Hirsch,et al.  Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.

[31]  R. Schinazi,et al.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1 , 1988, Antimicrobial Agents and Chemotherapy.

[32]  M. Wainberg,et al.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine , 1992, Journal of virology.

[33]  D. Richman,et al.  Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. , 1991, The Journal of infectious diseases.

[34]  E A Emini,et al.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.

[35]  K. Gelmon,et al.  Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy , 1989, AIDS.

[36]  J. Fitzgibbon,et al.  Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine , 1992, Antimicrobial Agents and Chemotherapy.